scholarly journals Hypoxia-Regulated miRNAs in Human Mesenchymal Stem Cells: Exploring the Regulatory Effects in Ischemic Disorders

2019 ◽  
Vol 20 (6) ◽  
pp. 1340
Author(s):  
Carmela Dell’Aversana ◽  
Francesca Cuomo ◽  
Chiara Botti ◽  
Ciro Maione ◽  
Annamaria Carissimo ◽  
...  

Human mesenchymal/stromal stem cells (hMSC) are the most promising cell source for adult cell therapies in regenerative medicine. Many clinical trials have reported the use of autologous transplantation of hMSCs in several disorders, but with limited results. To exert their potential, hMSCs could exhibit efficient homing and migration toward lesion sites among other effects, but the underlying process is not clear enough. To further increase the knowledge, we studied the co-regulation between hypoxia-regulated genes and miRNAs. To this end, we investigated the miRNA expression profile of healthy hMSCs in low oxygen/nutrient conditions to mimic ischemia and compared with cells of patients suffering from critical limb ischemia (CLI). miRNAs are small, highly conserved, non-coding RNAs, skilled in the control of the target’s expression level in a fine-tuned way. After analyzing the miRNOme in CLI-derived hMSC cells and healthy controls, and intersecting the results with the mRNA expression dataset under hypoxic conditions, we identified two miRNAs potentially relevant to the disease: miR-29b as a pathological marker of the disease and miR-638 as a therapeutic target. This study yielded a deeper understanding of stem cell biology and ischemic disorders, opening new potential treatments in the future.

2012 ◽  
Vol 2012 ◽  
pp. 1-12 ◽  
Author(s):  
Fernando de Sá Silva ◽  
Paula Nascimento Almeida ◽  
João Vitor Paes Rettore ◽  
Claudinéia Pereira Maranduba ◽  
Camila Maurmann de Souza ◽  
...  

Stem cells, both embryonic and adult, due to the potential for application in tissue regeneration have been the target of interest to the world scientific community. In fact, stem cells can be considered revolutionary in the field of medicine, especially in the treatment of a wide range of human diseases. However, caution is needed in the clinical application of such cells and this is an issue that demands more studies. This paper will discuss some controversial issues of importance for achieving cell therapy safety and success. Particularly, the following aspects of stem cell biology will be presented: methods for stem cells culture, teratogenic or tumorigenic potential, cellular dose, proliferation, senescence, karyotyping, and immunosuppressive activity.


Hematology ◽  
2003 ◽  
Vol 2003 (1) ◽  
pp. 398-418 ◽  
Author(s):  
George Q. Daley ◽  
Margaret A. Goodell ◽  
Evan Y. Snyder

Abstract Studies of the regenerating hematopoietic system have led to the definition of many of the fundamental principles of stem cell biology. Therapies based on a range of tissue stem cells have been widely touted as a new treatment modality, presaging an emerging new specialty called regenerative medicine that promises to harness stem cells from embryonic and somatic sources to provide replacement cell therapies for genetic, malignant, and degenerative conditions. Insights borne from stem cell biology also portend development of protein and small molecule therapeutics that act on endogenous stem cells to promote repair and regeneration. Much of the newfound enthusiasm for regenerative medicine stems from the hope that advances in the laboratory will be followed soon thereafter by breakthrough treatments in the clinic. But how does one sort through the hype to judge the true promise? Are stem cell biologists and the media building expectations that cannot be met? Which diseases can be treated, and when can we expect success? In this review, we outline the realms of investigation that are capturing the most attention, and consider the current state of scientific understanding and controversy regarding the properties of embryonic and somatic (adult) stem cells. Our objective is to provide a framework for appreciating the promise while at the same time understanding the challenges behind translating fundamental stem cell biology into novel clinical therapies.


Blood ◽  
2007 ◽  
Vol 110 (11) ◽  
pp. 217-217
Author(s):  
Ivana Rosova ◽  
Jan A. Nolta

Abstract Disorders such as peripheral artery disease cause hypoxic areas in tissues. Work from our group and others shows that stem cells appear to have innate mechanisms to respond to hypoxic conditions by migrating to the region of damage, and releasing trophic factors which initiate regeneration. Many tissues activate hepatocyte growth factor (HGF) as a response to ischemic injury. Multiple progenitor cell types express cMet, an HGF receptor. Mesenchymal stem cells (MSC) have been shown to improve regeneration of injured tissues in vivo, but their mechanisms of homing to the site of injury remain unclear. In the current studies we examined the potential for human MSC to repair injury caused by hind limb ischemia in immune deficient mice. We observed that hypoxic pre-conditioning of MSC upregulated expression of cMet, which could render the MSC more responsive to active HGF present at the site of ischemic injury. We first analyzed muscle lysates from mice that had undergone hind limb ischemia, vs sham-operated controls. ELISA results demonstrated that although a sham surgery caused a slight elevation in HGF levels 12 to 48 hours post surgery, ischemia caused a steady increase in HGF secretion from 12 hours to 48 hours post surgery. These data suggested that HGF might play a role in recruiting c-met+ MSC to the injury area. We next subjected primary human MSC to a 24-hr preconditioning in hypoxic (2 to 3% oxygen- actually tissue normoxia) vs. normoxic (21% oxygen, most commonly used in the incubator) conditions. MSC upregulated cMet in hypoxic conditions and then responded more robustly to HGF stimulation by signaling through cMet. Hypoxic pre-conditioning also caused signaling through a pro-survival Akt pathway, possibly improving the survival potential of MSC as they migrate in vivo. We next asked whether MSC are more motile in hypoxia. MSC were cultured in hypoxic or normoxic conditions +/− 25ng/ml HGF. While both HGF alone and a combination of hypoxia and HGF increased the cell migration capacity, treatment with hypoxia alone caused MSC to be the most migratory. These results suggest that hypoxic pre-conditioning may help MSC to migrate to the site of injury, while high active HGF levels in the tissue will hold the stem cells at the site of damage. Finally, to address the question of whether hypoxic pre-conditioning of MSC improves their tissue regeneration ability, we cultured them in hypoxic vs. normoxic conditions for 24 hrs and then transplanted them into NOD/SCID/B2m null mice that had undergone hind limb ischemia surgery one day prior to the transplant. Laser Doppler imaging showed significantly better blood flow recovery in the limbs of injured mice that were treated with pre-conditioned MSC, as compared to the saline control group. Mice that had received hypoxic pre-conditioned MSC improved bloodflow to the injured limb more rapidly than those transplanted with normoxic MSC, with a significant difference observed at day 5, demonstrating that hypoxic pre-conditioning increased the therapeutic potential of MSC. In summary, our data confirm that a 24 hour hypoxic pre-conditioning in vitro prior to transplantation improves the therapeutic potential of MSC, through activation of the pro-survival Akt pathway, upregulation of cMet, which allows them to be more responsive to the HGF activated at the site of ischemic injury, and an increased motility that allows them to more rapidly reach the area of injury.


2019 ◽  
Vol 46 (3) ◽  
pp. E10 ◽  
Author(s):  
Michael C. Jin ◽  
Zachary A. Medress ◽  
Tej D. Azad ◽  
Vanessa M. Doulames ◽  
Anand Veeravagu

Recent advances in stem cell biology present significant opportunities to advance clinical applications of stem cell–based therapies for spinal cord injury (SCI). In this review, the authors critically analyze the basic science and translational evidence that supports the use of various stem cell sources, including induced pluripotent stem cells, oligodendrocyte precursor cells, and mesenchymal stem cells. They subsequently explore recent advances in stem cell biology and discuss ongoing clinical translation efforts, including combinatorial strategies utilizing scaffolds, biogels, and growth factors to augment stem cell survival, function, and engraftment. Finally, the authors discuss the evolution of stem cell therapies for SCI by providing an overview of completed (n = 18) and ongoing (n = 9) clinical trials.


2014 ◽  
Vol 2014 ◽  
pp. 1-12 ◽  
Author(s):  
Botti Chiara ◽  
Caiafa Ilaria ◽  
Coppola Antonietta ◽  
Cuomo Francesca ◽  
Miceli Marco ◽  
...  

Human mesenchymal stem cells (hMSCs) are attractive for clinical and experimental purposes due to their capability of self-renewal and of differentiating into several cell types. Autologous hMSCs transplantation has been proven to induce therapeutic angiogenesis in ischemic disorders. However, the molecular mechanisms underlying these effects remain unclear. A recent report has connected MSCs multipotency to sirtuin families, showing that SIRT1 can regulate MSCs function. Furthermore, SIRT1 is a critical modulator of endothelial angiogenic functions. Here, we described the generation of an immortalized human mesenchymal bone marrow-derived cell line and we investigated the angiogenic phenotype of our cellular model by inhibiting SIRT1 by both the genetic and pharmacological level. We first assessed the expression of SIRT1 in hMSCs under basal and hypoxic conditions at both RNA and protein level. Inhibition of SIRT1 by sirtinol, a cell-permeable inhibitor, or by specific sh-RNA resulted in an increase of premature-senescence phenotype, a reduction of proliferation rate with increased apoptosis. Furthermore, we observed a consistent reduction of tubule-like formation and migration and we found that SIRT1 inhibition reduced the hypoxia induced accumulation of HIF-1α protein and its transcriptional activity in hMSCs. Our findings identify SIRT1 as regulator of hypoxia-induced response in hMSCs and may contribute to the development of new therapeutic strategies to improve regenerative properties of mesenchymal stem cells in ischemic disorders through SIRT1 modulation.


Author(s):  
Aparna Ramanathan ◽  
Ian A. J. Lorimer

AbstractIn spite of significant recent advances in our understanding of the genetics and cell biology of glioblastoma, to date, this has not led to improved treatments for this cancer. In addition to small molecule, antibody, and engineered virus approaches, engineered cells are also being explored as glioblastoma therapeutics. This includes CAR-T cells, CAR-NK cells, as well as engineered neural stem cells and mesenchymal stem cells. Here we review the state of this field, starting with clinical trial studies. These have established the feasibility and safety of engineered cell therapies for glioblastoma and show some evidence for activity. Next, we review the preclinical literature and compare the strengths and weaknesses of various starting cell types for engineered cell therapies. Finally, we discuss future directions for this nascent but promising modality for glioblastoma therapy.


2020 ◽  
Author(s):  
Ayushman Sharma ◽  
Allan B. Dietz

AbstractImportanceTransplantation of adipose-derived (mesenchymal) stem cells (ADSCs) are currently under investigation for numerous novel regenerative cell therapies of the head, neck and periphery. Critical to the development of these techniques is the availability of large-animal models that can be used to test the safety and efficacy of these approaches in a manner that provides source material (in this case MSC) analogous to those developed in humans.ObjectiveTo describe the surgical technique and laboratory procedures for harvesting and isolating porcine ADSCs that are functionally equivalent to human ADSCs without sacrificing the donor animal.MethodsThe reagents and methods used in the porcine model described were purposefully focused to be able to be sufficiently analogous to those used in humans such that data developed using these techniques should support the use of porcine models for regulatory submissions.ResultsWe describe a method and confirm the activity of functionally analogous adipose derived porcine MSC. Two conditions were critical to move gain analogous performance: the cells needed to be incubated at porcine body temperature (39°C) and the cells were more sensitive to initial plating densities with plating densities of 20,000 cells/cm2 being optimal.DiscussionThis approach will allow reproducible and predictable use of an autologous large-animal model for testing AMDSC therapies.


2021 ◽  
Vol 53 (3) ◽  
pp. 415-427
Author(s):  
Anggraini Barlian ◽  
Marselina Irasonia Tan ◽  
Ergha Widya Sarjana ◽  
Noviana Vanawati

Previous research has proven that 10% platelet-rich plasma (PRP) can enhance growth and differentiation of human adipose derived stem cells (hADSC) grown on silk fibroin scaffold into chondrocytes. A low oxygen concentration (hypoxia) condition is an important factor that potentially affects the ability of hADSC to grow and differentiate. The objective of this research was to analyze the difference in growth and differentiation capacity of hADSC grown on salt leached silk fibroin scaffold supplemented by 10% PRP under normoxic and hypoxic conditions. The growth capacity of the hADSC was determined by MTT assay and differentiation was tested using glycosaminoglycan (GAG) content analysis, while chondrocyte markers were visualized with the immunocytochemistry (ICC) method. This research observed hADSC proliferation under normoxic and hypoxic conditions for 21 days. Visualization of type 2 collagen showed that it was more abundant under hypoxia compared to normoxia.  HIF-1α was only detected in the hADSC cultured in hypoxic conditions. In conclusion, culture under hypoxic conditions increases the capacity of hADSC to grow and differentiate into chondrocytes. This is the first study that has shown that hypoxia is able to enhance the proliferation and differentiation of hADSC grown on 3D salt leached silk fibroin scaffold supplemented by 10% PRP.


Author(s):  
Malgorzata Witkowska-Zimny ◽  
Edyta Wrobel

AbstractRecently, stem cell biology has become an interesting topic, especially in the context of treating diseases and injuries using transplantation therapy. Several varieties of human stem cells have been isolated and identified in vivo and in vitro. Ideally, stem cells for regenerative medical application should be found in abundant quantities, harvestable in a minimally invasive procedure, then safely and effectively transplanted to either an autologous or allogenic host. The two main groups of stem cells, embryonic stem cells and adult stem cells, have been expanded to include perinatal stem cells. Mesenchymal stem cells from perinatal tissue may be particularly useful in the clinic for autologous transplantation for fetuses and newborns, and after banking in later stages of life, as well as for in utero transplantation in case of genetic disorders.This review highlights the characteristics and therapeutic potential of three human mesenchymal stem cell types obtained from perinatal sources: Wharton’s jelly, the amnion, and the chorion.


Sign in / Sign up

Export Citation Format

Share Document